Jaguar Animal Health Inc (JAGX)vsBeiGene, Ltd. (ONC)
JAGX
Jaguar Animal Health Inc
$0.97
+0.20%
HEALTHCARE · Cap: $4.73M
ONC
BeiGene, Ltd.
$327.21
-0.98%
HEALTHCARE · Cap: $34.29B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 19309% more annual revenue ($5.74B vs $29.57M). ONC leads profitability with a 8.9% profit margin vs -115.4%. ONC earns a higher WallStSmart Score of 54/100 (C-).
JAGX
Hold48
out of 100
Grade: D+
ONC
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for JAGX.
Margin of Safety
+81.1%
Fair Value
$1857.02
Current Price
$327.21
$1529.81 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 50.2%
Revenue surging 816.0% year-over-year
Conservative balance sheet, low leverage
Revenue surging 35.5% year-over-year
Earnings expanding 16971.0% YoY
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -411.6% — below average capital efficiency
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : JAGX
The strongest argument for JAGX centers on Operating Margin, Revenue Growth, Debt/Equity. Revenue growth of 816.0% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 35.5% demonstrates continued momentum.
Bear Case : JAGX
The primary concerns for JAGX are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 74.6x leaves little room for execution misses.
Key Dynamics to Monitor
ONC carries more volatility with a beta of 0.49 — expect wider price swings.
JAGX is growing revenue faster at 816.0% — sustainability is the question.
ONC generates stronger free cash flow (161M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ONC scores higher overall (54/100 vs 48/100) and 35.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Jaguar Animal Health Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Jaguar Health, Inc., a commercial-stage pharmaceutical company, focuses on developing prescription drugs for people and animals with gastrointestinal upset, specifically chronic debilitating diarrhea. The company is headquartered in San Francisco, California.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?